Cargando…

Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States

BACKGROUND: Fibromyalgia (FM) is a chronic disorder characterized by widespread, persistent pain. Prospective and retrospective studies have demonstrated substantial health-care costs associated with FM in a number of countries. This study evaluated and compared health-resource use (HRU) and associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Knight, Tyler, Schaefer, Caroline, Chandran, Arthi, Zlateva, Gergana, Winkelmann, Andreas, Perrot, Serge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637123/
https://www.ncbi.nlm.nih.gov/pubmed/23637545
http://dx.doi.org/10.2147/CEOR.S41111
_version_ 1782267411928449024
author Knight, Tyler
Schaefer, Caroline
Chandran, Arthi
Zlateva, Gergana
Winkelmann, Andreas
Perrot, Serge
author_facet Knight, Tyler
Schaefer, Caroline
Chandran, Arthi
Zlateva, Gergana
Winkelmann, Andreas
Perrot, Serge
author_sort Knight, Tyler
collection PubMed
description BACKGROUND: Fibromyalgia (FM) is a chronic disorder characterized by widespread, persistent pain. Prospective and retrospective studies have demonstrated substantial health-care costs associated with FM in a number of countries. This study evaluated and compared health-resource use (HRU) and associated costs related to FM in routine clinical practice across the US, France, and Germany. METHODS: Two separate, cross-sectional, observational studies of subjects with FM were conducted: one in the US and one in France and Germany. HRU related to prescription medication, physician office visits, diagnostic tests, and hospitalizations was abstracted from chart review; patient out-of-pocket costs and lost productivity were collected via subject self-report. Costs were assigned to HRU based on standard algorithms. Direct and indirect costs were evaluated and compared by simple linear regression. RESULTS: A total of 442 subjects (203 US, 70 France, 169 Germany) with FM were analyzed. The mean (standard deviation) age in the US, France, and Germany was 47.9 (10.9), 51.2 (9.5), and 49.2 (9.8), respectively (P = 0.085). Most subjects were female (95% US, 83% France, 80% Germany) (P < 0.001). Adjusted annual direct costs per subject for FM were significantly higher in the US ($7087) than in France ($481, P < 0.001) or Germany ($2417, P < 0.001). Adjusted mean annual indirect costs per subject for FM were lower in the US ($6431) than in France ($8718) or Germany ($10,001), but represented a significant proportion of total costs in all countries. CONCLUSION: The significant HRU and costs associated with FM in the US, France, and Germany documented in this study highlight the substantial global economic burden of FM. Indirect costs represented a significant proportion of the total costs, particularly in Europe. Comparisons between the three countries show differences in HRU, with significantly higher direct costs in the US compared with France and Germany.
format Online
Article
Text
id pubmed-3637123
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-36371232013-05-01 Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States Knight, Tyler Schaefer, Caroline Chandran, Arthi Zlateva, Gergana Winkelmann, Andreas Perrot, Serge Clinicoecon Outcomes Res Original Research BACKGROUND: Fibromyalgia (FM) is a chronic disorder characterized by widespread, persistent pain. Prospective and retrospective studies have demonstrated substantial health-care costs associated with FM in a number of countries. This study evaluated and compared health-resource use (HRU) and associated costs related to FM in routine clinical practice across the US, France, and Germany. METHODS: Two separate, cross-sectional, observational studies of subjects with FM were conducted: one in the US and one in France and Germany. HRU related to prescription medication, physician office visits, diagnostic tests, and hospitalizations was abstracted from chart review; patient out-of-pocket costs and lost productivity were collected via subject self-report. Costs were assigned to HRU based on standard algorithms. Direct and indirect costs were evaluated and compared by simple linear regression. RESULTS: A total of 442 subjects (203 US, 70 France, 169 Germany) with FM were analyzed. The mean (standard deviation) age in the US, France, and Germany was 47.9 (10.9), 51.2 (9.5), and 49.2 (9.8), respectively (P = 0.085). Most subjects were female (95% US, 83% France, 80% Germany) (P < 0.001). Adjusted annual direct costs per subject for FM were significantly higher in the US ($7087) than in France ($481, P < 0.001) or Germany ($2417, P < 0.001). Adjusted mean annual indirect costs per subject for FM were lower in the US ($6431) than in France ($8718) or Germany ($10,001), but represented a significant proportion of total costs in all countries. CONCLUSION: The significant HRU and costs associated with FM in the US, France, and Germany documented in this study highlight the substantial global economic burden of FM. Indirect costs represented a significant proportion of the total costs, particularly in Europe. Comparisons between the three countries show differences in HRU, with significantly higher direct costs in the US compared with France and Germany. Dove Medical Press 2013-04-23 /pmc/articles/PMC3637123/ /pubmed/23637545 http://dx.doi.org/10.2147/CEOR.S41111 Text en © 2013 Knight et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Knight, Tyler
Schaefer, Caroline
Chandran, Arthi
Zlateva, Gergana
Winkelmann, Andreas
Perrot, Serge
Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States
title Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States
title_full Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States
title_fullStr Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States
title_full_unstemmed Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States
title_short Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States
title_sort health-resource use and costs associated with fibromyalgia in france, germany, and the united states
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637123/
https://www.ncbi.nlm.nih.gov/pubmed/23637545
http://dx.doi.org/10.2147/CEOR.S41111
work_keys_str_mv AT knighttyler healthresourceuseandcostsassociatedwithfibromyalgiainfrancegermanyandtheunitedstates
AT schaefercaroline healthresourceuseandcostsassociatedwithfibromyalgiainfrancegermanyandtheunitedstates
AT chandranarthi healthresourceuseandcostsassociatedwithfibromyalgiainfrancegermanyandtheunitedstates
AT zlatevagergana healthresourceuseandcostsassociatedwithfibromyalgiainfrancegermanyandtheunitedstates
AT winkelmannandreas healthresourceuseandcostsassociatedwithfibromyalgiainfrancegermanyandtheunitedstates
AT perrotserge healthresourceuseandcostsassociatedwithfibromyalgiainfrancegermanyandtheunitedstates